Enterome

This month, we’re raising #BloodCancer awareness together! 📣 RT to spread the word! 🔁 #BloodCancerAwarenessMonth

Watch this insightful interview of Dr. Stephen Ansell from the @MayoClinic on @VJHemOnc to learn more about our novel immune therapy, EO2463, currently being evaluated in the phase 2 SIDNEY trial: youtu.be/oIZIOCDZb7w?si…

It’s our first-ever Dare to Dream Day! Show your support by 1) retweeting or creating a tweet with our new GIF 👇 and 2) donating today! Because kids deserve better. With your support, dreams can come true. Donate now, and your gift will be TRIPLED 👉 bit.ly/4c9SkDI #WeDareToDream4Kids

.@EnteromeSA data was presented at #ASCO24 It highlighted complete response rates in non-Hodgkin lymphoma patients treated with their therapeutic vaccine combined with standard therapies. @ASCO🔎Learn more about the drug and LLS TAP’s role in it: 👉msg.lls.org/3X96Ur6

More exciting news is expected tomorrow at #ASCO24 from LLS TAP partners @EnteromeSA and @CaribouBio. @ASCO 🔎 Learn more about Caribou’s next-generation off-the-shelf cell therapy and Enterome’s therapeutic vaccine and how TAP is supporting their work 👉 bit.ly/3yA1PO4

Excited to be at @ASCO's annual meeting #ASCO24! Stay tuned to our channels as our LLS Therapy Acceleration Program (TAP) partners present new data on #BloodCancer science and innovation. Learn more about TAP 👉 bit.ly/3Kns3pJ

We're attending the the 2024 @Jefferies Global Healthcare Conference which is taking place June 4-6 in NYC. Our CEO Pierre Belichard and CFO Christelle Dumoussaud will be available for 1:1 meetings. #JefferiesHealthcare

What's the deal with clinical trials? 🤔 Valerie's insights as a #lymphoma survivor may interest you 👉 bit.ly/3QOeeEq #ClinicalTrialsDay

ROSALIE Trial of EO2401/Nivolumab/Bevacizumab in Recurrent Glioblastoma Concludes onclive.com/view/rosalie-t… via @onclive

Enterome’s OncoMimics™ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma globenewswire.com/en/news-releas…

With a liquid biopsy, we can learn what’s going on inside a patient’s body by examining circulating tumor DNA (ctDNA). Explore how this technology works, its current limitations and future prospects, from our @AnthonyLucci1: fal.cn/3ArJS #LiquidBiopsy #EndCancer

"The CLAUDE study (EOCRC1-22; NCT05350501) is the 1st trial to use liquid biopsy monitoring to measure ctDNA clearance as an indicator of OncoMimics™ immunotherapy efficacy." trial info crcmrd.com/?avada_portfol… video with PI @adasarimd crcmrd.com/?p=2590

We're pleased to announce first patient dosed in Ph2 trial (CLAUDE) evaluating EO240 in #colorectalcancer with ctDNA-defined Minimal Residual Disease. EO2040 is Enterome’s fourth OncoMimics peptide-based #immunotherapy to enter #clinical development: lnkd.in/eSK2SRAC

[Health for Life Capital™ portfolio] 👏 Congrats! @EnteromeSA & @S_O_Cheese selected, over 840 applicants, as candidates for the investment plan “France 2030” led by the French General Secretary for Investment. #Microbiome #foodscience @IdeCremoux

Ils innovent et portent des projets d’avenir, prometteurs et responsables. Pour le pays, leur rôle demain sera clé. Voici les 125 lauréats French Tech 2030. Nous allons les soutenir avec force.

We look forward to presenting new data from our Phase 2 #clinicaltrial (ROSALIE), evaluating our lead #OncoMimics #immunotherapy candidate EO2401 in patients with first progression/recurrence of #glioblastoma, at the @ASCO Annual Meeting this year. lnkd.in/euzwwHBa

Our management team will attend BioTrinity 2023 in London. We look forward to discussing our first-in-class immunomodulatory drugs, including our #OncoMimics™ immunotherapies as potential breakthrough drugs for the treatment of solid and liquid tumors. #BioTrinity #biotech

Enterome's team will attend #BIOEuropeSpring to meet potential partners and discuss the promising progress of our #clinical stage #OncoMimics™ peptide-based #immunotherapies. To arrange a meeting with the Enterome team, BIO-Europe’s partnering platform is now open.

Next week our CBO, Anne Dagallier, will attend the Glioblastoma Drug Development Summit to discuss the progress of our Phase 2 ROSALIE #clinicalstudy evaluating lead #immunotherapy, EO2401, in patients with first progression/recurrence of #glioblastoma #GBMSummit2023 #gbmresearch

Many thanks to @Labiotech_eu for featuring Enterome's CEO, Pierre Belichard on #BeyondBiotech. Pierre discusses the potential of our #OncoMimics pipeline produced using our Mimicry drug discovery platform & targeting difficult-to-treat cancers (18.13 mins) lnkd.in/dF_js_zs